Premium
Overexpression of the metastasis‐associated gene MTA3 correlates with tumor progression and poor prognosis in hepatocellular carcinoma
Author(s) -
Wang Chuanxi,
Li Guanzhen,
Li Jiamei,
Li Jie,
Li Tao,
Yu Jinyu,
Qin Chengyong
Publication year - 2017
Publication title -
journal of gastroenterology and hepatology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.214
H-Index - 130
eISSN - 1440-1746
pISSN - 0815-9319
DOI - 10.1111/jgh.13680
Subject(s) - hepatocellular carcinoma , gene knockdown , immunohistochemistry , metastasis , oncogene , medicine , pathology , cancer research , cancer , gene , biology , cell cycle , biochemistry
Abstract Background and Aim Hepatocellular carcinoma (HCC) is one of the most common and aggressive cancers in the world. However, there remains a lack of effective diagnostic and treatment markers. We aimed to explore metastasis‐associated protein 3 (MTA3) expression and function in HCC and its relationship with clinicopathological factors. Methods We investigated the expression pattern and clinicopathological significance of MTA3 in 90 patients with HCC via immunohistochemistry and explored MTA3 function via gene knockdown of MTA3 . Results MTA3 was overexpressed in HCC cell nuclei and downregulated in HCC cell cytoplasm. The former finding correlated with metastasis ( P = 0.010) and poor prognosis ( P = 0.018). In addition, deleting MTA3 inhibited HCC cell growth, invasion, and metastasis in vitro , as shown in the colony formation, migration, and wound‐healing assays. Conclusions These results indicate that MTA3 is an oncogene of HCC, predicts poor prognosis of HCC, and may be a future marker of HCC treatment.